IM8 Becomes Official Nutrition Partner of the NBA in Australia and Southeast Asia
PRE sits 86% above its 52-week low of $11.365.
Summary
Prenetics' IM8 brand announced a multi-year collaboration with the NBA as the Official Nutrition Partner in Australia and Southeast Asia, targeting approximately 660 million people.
Key Events · M&A and Partnerships · PRE
-
NBA Partnership Announced
Under a multi-year collaboration, IM8 has been named the Official Nutrition Partner of the NBA in Australia and eight Southeast Asian markets.
-
Regional Reach
The partnership targets approximately 660 million people across Australia and Southeast Asia, pairing basketball-loving communities with premium health and wellness demand.
-
Fan Activation Planned
In 2027, IM8 will host an activation at NBA House in the region, one of the league's signature fan events.
-
Brand Momentum
This follows Q2 2026 revenue of $46.5M (up 288% YoY) and raised FY2026 guidance of $220-230M, with IM8 as the primary growth driver.
Analysis · PRE · Life Sciences
A multi-year partnership with the NBA positions Prenetics' IM8 brand as the Official Nutrition Partner across Australia and eight Southeast Asian markets. This marks a significant brand-building milestone for IM8, the company's primary growth engine—Q2 2026 revenue reached $46.5M, up 288% year-over-year, and FY2026 guidance was recently raised to $220-230M. The NBA's global reach and credibility with basketball fans directly support IM8's premium positioning and expansion strategy, with a fan activation at NBA House planned for 2027. The partnership targets approximately 660 million people in the region, a substantial addressable audience for a consumer health brand.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 29.1% of the 1500 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.51%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRE was trading at $21.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $362.8M. The 52-week trading range was $11.37 to $27.24. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.